Defining the role of renal transplantation in the modern management of multiple myeloma and other plasma cell dyscrasias

Nephron - Clinical Practice

Volumn 120, Issue 4, 2012, Pages

  Bansal, Tarun ^a   Garg, Anshu ^a   Snowden, John A ^a,b   McKane, William ^a  

^a SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Amyloidosis; Autologous stem cell transplantation; Light chain deposition disease; Monoclonal immunoglobulin deposition disease; Multiple myeloma; Plasma cell dyscrasias; Renal transplantation

Indexed keywords

BORTEZOMIB; CORTICOSTEROID; CYCLOSPORIN; DEXAMETHASONE; DOXORUBICIN; LENALIDOMIDE; MELPHALAN; PARAPROTEIN; THALIDOMIDE; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; AMYLOIDOSIS; HUMAN; IMMUNOGLOBULIN DEPOSITION; KIDNEY DYSFUNCTION; KIDNEY TRANSPLANTATION; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; PLASMA CELL DYSCRASIA; PRIORITY JOURNAL; REVIEW; PARAPROTEINEMIAS; PATIENT SELECTION; PROGNOSIS;

HUMANS; KIDNEY TRANSPLANTATION; MULTIPLE MYELOMA; PARAPROTEINEMIAS; PATIENT SELECTION; PROGNOSIS;

EID: 84867220302     PISSN: None     EISSN: 16602110     Source Type: Journal    
DOI: 10.1159/000341760     Document Type: Review

References (40)

1. Kyle RA, Rajkumar SV: MULTIPLE myeloma. N Engl J Med 2004; 351: 1860-1873.
2. BCSH and UKMF Guidelines on the Management and Diagnosis of Multiple Myeloma, 2010.
3. Brenner H, Gondos A, Pulte D: EXPECTED long-Term survival of patients diagnosed with multiple myeloma in 2006-2010. Haematologica 2009; 94: 270-275.
4. Eleutherakis-Papaiakovou V, Bamias A, Gika D, et al: RENAL failure in multiple myeloma: Incidence, correlations, and prognostic significance. Leuk Lymphoma 2007; 48: 337-341. (Pubitemid 46994883)
5. Basnayake K, Stringer SJ, Hutchison CA, Cockwell P: THE biology of immunoglobulin-free light chains and kidney injury. Kidney Int 2011; 79: 1289-1301.
6. Wirk B: RENAL failure in multiple myeloma: A medical emergency. Bone Marrow Transplant 2011, pp 1-13.
7. Korbet SM, Schwartz MM: MULTIPLE myeloma. J Am Soc Nephrol 2006; 17: 2533-2545. (Pubitemid 44300969)
8. Augustson BM, Begum G, Dunn JA, et al: EARLY mortality after diagnosis of multiple myeloma: Analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002 -Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2005; 23: 9219-9226.
9. Rayner HC, Haynes AP, Thompson JR, et al: PERSPECTIVES in multiple myeloma: Survival, prognostic factors and disease complications in a single center between 1975 and 1988. Q J Med 1991; 79: 517-525.
10. Turesson I, Velez R, Kristinsson SY, Landgren O: PATTERNS of improved survival in patients with multiple myeloma in the twentyfirst century: A population-based study. J Clin Oncol 2010; 28: 830-834.
11. Penfield J: MULTIPLE myeloma in end-stage renal disease. Semin Dial 2006; 19: 329-334. (Pubitemid 44091709)
12. Kumar SK, Rajkumar SV, Dispenzieri A, et al: IMPROVED survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516-2520.
13. Ludwig H, Adam Z, Greil R, et al: REVERSAL of acute renal impairment by bortezomibdoxorubicin-Dexamethasone in multiple myeloma. Results from a phase II study. Haematologica 2009; 94(suppl):154, abstr 385.
14. Tosi P, Zamagni E, Cellini C, et al: THALIDOMIDE alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. Eur J Haematol 2004; 73: 98-103. (Pubitemid 38980109)
15. Leung N, Gertz MA, Zeldenrust SR, et al: IMPROVEMENT of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum-free light chains. Kidney Int 2008; 73: 1282-1288. (Pubitemid 351693147)
16. Hutchison CA, Bradwell AR, Cook M, et al: TREATMENT of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. Clin J Am Soc Nephrol 2009; 4: 745-754.
17. Haynes RJ, Read S, Collins GP, et al: PRESENTATION and survival of patients with severe acute kidney injury and multiple myeloma: 20-year experience from a single centre. Nephrol Dial Transplant 2009; 25: 419-426.
18. Hutchison CA, Cockwell P, Stringer S, et al: EARLY reduction of serum-free light chains associates with renal recovery in myeloma kidney. J Am Soc Nephrol 2011; 22: 1129-1136.
19. Hutchison CA, Cook M, Heyne N, et al: EUROPEAN trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): A randomised control trial. Trials. Clinicaltrials.gov/ct2/show/NCT00700531.
20. Fudaba Y, Spitzer TR, Shaffer J, et al: MYELOMA responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: In vivo and in vitro analyses. Am J Transplant 2006; 6: 2121-2133. (Pubitemid 44199546)
21. Combined bone marrow transplantation (BMT) and renal transplant for multiple myeloma (MM) with end-stage renal disease (ESRD) NCT00854139 Clinical Trials.gov
22. Heher EC, Spitzer TR, Goes NB: LIGHT chains: Heavy burden in kidney transplantation. Transplantation 2009; 87: 947-952.
23. Van Bommel EFH: MULTIPLE myeloma treatment in dialysis-Dependent patients: To transplant or not to transplant? Nephrol Dial Transplant 1996; 11: 1486-1487. (Pubitemid 26241449)
24. De Lima JJ, Kourilsky O, Meyrier A, et al: KIDNEY transplant in multiple myeloma. Early recurrence in the graft with sustained normal renal function. Transplantation 1981; 31: 223.
25. Walker F, Bear RA: RENAL transplantation in light-Chain multiple myeloma. Am J Nephrol 1983; 3: 34.
26. Dagher F, Sammett D, Abbi R, et al: RENAL transplantation in multiple myeloma. Case report and review of the literature. Transplantation 1996; 62: 1577-1580.
27. Tsakiris DJ, Stel VS, Finne P, et al: INCIDENCE and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-Chain deposit disease: An ERA-EDTA Registry study. Nephrol Dial Transplant 2010; 25: 1200-1206.
28. Spitzer TR, Sykes M, Tolkoff-Rubin N, et al: LONG-Term follow-Up of recipients of combined human leukocyte antigen-matched bone marrow and kidney transplantation for multiple myeloma with end-stage renal disease. Transplantation 2011; 91: 672-676.
29. European Best Practice Guidelines for Renal Transplantation (Part 1). Nephrol Dial Transplant 2000; 15(SUPPL7
30. Heher EC, Spitzer TR, Goes NB: LIGHT chains: Heavy burden in kidney transplantation. Transplantation 2009; 87: 947-952.
31. Leung N, Lager DJ, Gertz MA, et al: LONGTERM outcome of renal transplantation in light-Chain deposition disease. Am J Kidney Dis 2004; 43: 147-153. (Pubitemid 38049446)
32. Royer B, Arnulf B, Martinez F, et al: HIGHDOSE chemotherapy in light chain or light and heavy chain deposition diseases. Kidney Int 2004; 65: 642-648. (Pubitemid 38130660)
33. Hassoun H, Flombaum C, D'Agati VD, et al: HIGH-Dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease. Bone Marrow Transplantation 2008; 42: 405-412.
34. Lorenz E, Gertz M, Fervenza FC, et al: LONGTERM outcome of autologous stem cell transplantation in light chain deposition disease. Nephrol Dial Transplant 2008; 23: 2052-2057. (Pubitemid 351768166)
35. Girnius S, Seldin DC, Quillen K, et al: LONGTERM outcome of patients with monoclonal Ig deposition disease treated with high-Dose melphalan and stem cell transplantation. Bone Marrow Transplant 2011; 46: 161-162.
36. Bansal T, Hossain R, McKane W, Snowden JA: SAFETY and efficacy of high-Dose melphalan and autologous stem cell transplantation prior to renal allograft in end-stage renal failure secondary to monoclonal immunoglobulin deposition disease. Cell Ther Transplant 2011; 3:e.000091.01. doi:10.3205/ ctt-2011-en-000091.01.
37. Hartmann A, Holdaas H, Fauchald P, et al: FIFTEEN years' experience with renal transplantation in systemic amyloidosis. Transplant Int 1992; 5: 15-18.
38. Leung N, Griffin MD, Dispenzieri A, et al: LIVING donor kidney and autologous stem cell transplantation for primary systemic amyloidosis (AL) with predominant renal involvement. Am J Transplant 2005; 5: 1660-1670. (Pubitemid 40910448)
39. Sattianayagam PT, Gibbs SDJ, Gillmore JD, et al: SOLID organ transplantation in AL amyloidosis. Am J Transplant 2010; 10: 2124-2131.
40. Herrmann SM, Gertz MA, Stegall MD, et al: LONG-Term out comes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation. Nephrol Dial Transplant 2011; 26: 2032-2036.